Baxter’s Colleague moves ahead
This article was originally published in The Gray Sheet
Executive Summary
Firm announces conditional FDA approval on Dec. 14 of a corrective action plan for the Colleague drug infusion pump. The company also reported filing an updated 510(k) for the device. Upon agency clearance of the 510(k) and final approval of the corrective plan, Baxter will begin field upgrades to more than 200,000 pumps in U.S. hospitals. The pumps have been off the market for more than a year, following an October 2005 seizure by FDA. In June Baxter signed a consent decree with the agency requiring the firm to comply with manufacturing quality control regulations before U.S. sales can resume (1"The Gray Sheet" July 3, 2006, p. 4)...
You may also be interested in...
Baxter’s Ipump returns
Firm will resume sales of Ipump pain management infusion pumps in the second quarter after announcing 510(k) clearance of an upgraded version Feb. 6. Baxter had placed Ipump "on hold" in July 2005 while it developed hardware and software to reduce error codes and improve programming. The firm is making similar improvements to its Colleague and Syndeo infusion pumps. The latter malfunction-prone devices have been off the market since a seizure by FDA in October 2005, followed by a June consent decree forbidding their sale until Baxter gets its manufacturing system back into compliance. The firm announced a 510(k) filing for an updated Colleague and approval of a corrective action plan in December (1"The Gray Sheet" Dec. 18, 2006, In Brief)...
Baxter’s Colleague Consent Decree Enjoins Sales, Expands Obligations
Baxter signed a consent decree with FDA June 29 forbidding the sale of its widely used but malfunction-prone Colleague intravenous infusion pump until the firm complies with manufacturing quality regulations
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.